Want to see INBX full AI Analyst Report?
INBX Stock Chart & Stats
$85.32
-$0.31(-2.00%)
At close: 4:00 PM EST
$85.32
-$0.31(-2.00%)
Day’s Range― - ―
52-Week Range$20.55 - $155.29
Previous CloseN/A
Volume23.61K
Average Volume (3M)342.76K
Market Cap
$1.28B
Enterprise Value$1.23B
Total Cash (Recent Filing)$161.66M
Total Debt (Recent Filing)$5.90M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 19, 2026EPS Estimate
-2.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.39
Shares Outstanding14,671,186
10 Day Avg. Volume361,934
30 Day Avg. Volume342,763
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue943.29
Enterprise Value/Gross Profit-2.65K
Enterprise Value/Ebitda-10.56
Forecast
1Y Price Target
$277.50Price Target Upside225.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone - BLA AcceptanceBLA acceptance is a durable de-risking step that moves ozekibart from trial-stage toward commercialization. If approved, it would be the company's first product and the first systemic therapy for this rare cancer, creating a unique market position and potential sustained revenue stream.
Robust Clinical Efficacy Across ProgramsStrong objective response rates and planned Phase 3 progression indicate reproducible biology for INBRX-106, supporting a multi-indication immuno-oncology strategy. Durable clinical signals across assets expand the company's addressable market and lessen single-asset binary risk over months.
Material Liquidity ExpansionAn enlarged facility and $100M immediate draw materially extend runway to fund late-stage trials and regulatory activities. Improved access to capital reduces near-term financing urgency and supports continued clinical execution and potential commercialization planning.
Bears Say
High Cash Burn And Negative Free Cash FlowSustained, large negative operating and free cash flows indicate the company cannot self-fund development or commercialization. Over the medium term this raises persistent financing needs, increases dilution risk, and constrains strategic flexibility if clinical timelines slip.
Negative Shareholders' EquityNegative equity signals multi-period losses and weakened balance-sheet flexibility. This structural capital shortfall limits borrowing capacity, complicates covenant negotiations, and heightens sensitivity to adverse outcomes or trial delays that could force dilutive financing.
Dependence On Complex External FinancingWhile providing liquidity, the facility's warrants, pledged collateral and discretionary tranche create dilution risk and conditional funding. Long-term execution thus remains tied to external providers' discretion and could constrain strategic choices or governance during critical commercialization phases.
Inhibrx Biosciences Inc News
INBX FAQ
What was Inhibrx Biosciences, Inc.’s price range in the past 12 months?
Inhibrx Biosciences, Inc. lowest stock price was $20.55 and its highest was $155.29 in the past 12 months.
What is Inhibrx Biosciences, Inc.’s market cap?
Inhibrx Biosciences, Inc.’s market cap is $1.28B.
When is Inhibrx Biosciences, Inc.’s upcoming earnings report date?
Inhibrx Biosciences, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 31 days.
How were Inhibrx Biosciences, Inc.’s earnings last quarter?
Inhibrx Biosciences, Inc. released its earnings results on May 14, 2026. The company reported -$2.15 earnings per share for the quarter, missing the consensus estimate of -$1.675 by -$0.475.
Is Inhibrx Biosciences, Inc. overvalued?
According to Wall Street analysts Inhibrx Biosciences, Inc.’s price is currently Undervalued.
Does Inhibrx Biosciences, Inc. pay dividends?
Inhibrx Biosciences, Inc. pays a Notavailable dividend of $0.85 which represents an annual dividend yield of N/A. See more information on Inhibrx Biosciences, Inc. dividends here
What is Inhibrx Biosciences, Inc.’s EPS estimate?
Inhibrx Biosciences, Inc.’s EPS estimate is -2.28.
How many shares outstanding does Inhibrx Biosciences, Inc. have?
Inhibrx Biosciences, Inc. has 14,671,186 shares outstanding.
What happened to Inhibrx Biosciences, Inc.’s price movement after its last earnings report?
Inhibrx Biosciences, Inc. reported an EPS of -$2.15 in its last earnings report, missing expectations of -$1.675. Following the earnings report the stock price went down -6.474%.
Which hedge fund is a major shareholder of Inhibrx Biosciences, Inc.?
Currently, no hedge funds are holding shares in INBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibrx Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$277.50 (225.25% Upside)
$277.50 (225.25% Upside)
Blogger Sentiment
Bullish
INBX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 240.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
269.98%
12-Months-Change
Fundamentals
Return on Equity
-563.89%
Trailing 12-Months
Asset Growth
-24.18%
Trailing 12-Months
Company Description
Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
INBX Stock 12 Month Forecast
Average Price Target
$277.50
▲(225.25% Upside)
Technical Analysis
Prothena
―
CytomX Therapeutics
―
Humacyte
―
Monte Rosa Therapeutics
―
Candel Therapeutics
―
Ownership Overview
9.66% Insiders
8.32% Mutual Funds
0.11% Other Institutional Investors
70.09% Public Companies and
Individual Investors